Physician profile
Mark Swofford
NPI 1245238484
$4,054.00
in general payments reported to CMS, 2019-2025
52 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $181 · 2021: $369 · 2022: $392 · 2023: $503 · 2024: $964 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $366.94 | 2019-2025 | Lithovue, Tria Firm, Ams 700 |
| Janssen Biotech, INC. | $282.66 | 2023-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.73 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $258.07 | 2020-2024 | Dificid |
| Urogen Pharma, INC. | $230.98 | 2024-2025 | |
| Covidien LP | $209.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $175.44 | 2021-2023 | |
| Procept Biorobotics Corporation | $172.66 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Takeda Pharmaceuticals U.S.A., INC. | $159.33 | 2021-2025 | Gattex |
| Regeneron Healthcare Solutions, INC. | $126.23 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $106.39 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $106.33 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $100.86 | 2019-2024 | Injectafer |
| Endo USA, INC. | $99.10 | 2024-2025 | Xiaflex |
| Abbvie INC. | $94.15 | 2022-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Swofford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.